Loading clinical trials...
Loading clinical trials...
A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
UCSF Health St. Mary's Hospital
San Francisco, California, United States
Heart and Vascular Center
San Francisco, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Norton Hospital
Louisville, Kentucky, United States
Norton Pulmonary Specialists
Louisville, Kentucky, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Center for Advanced Lung Care
Providence, Rhode Island, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
HUB Hôpital Erasme
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Start Date
November 10, 2025
Primary Completion Date
July 18, 2028
Completion Date
July 18, 2028
Last Updated
March 18, 2026
36
ESTIMATED participants
PF-07868489
DRUG
Lead Sponsor
Pfizer
NCT06899815
NCT07462260
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07057466